Fagron N.V.
A global pharmaceutical compounding company focused on personalized medicine.
FAGR | BR
Overview
Corporate Details
- ISIN(s):
- BE0003874915
- LEI:
- 549300TRKRUFK2RRG779
- Country:
- Belgium
- Address:
- Venecoweg 20A, 9810 Nazareth
- Website:
- https://fagron.com/
- Sector:
- Manufacturing
Description
Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 07:00 |
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and …
|
English | 180.2 KB | ||
| 2025-11-24 07:00 |
Fagron versterkt leiderschap in de EMEA-regio met overnames en kondigt belangri…
|
Dutch | 207.9 KB | ||
| 2025-11-14 18:00 |
141125_Press release progress share buy back program Fagron - ENG.pdf
|
English | 154.6 KB | ||
| 2025-11-14 18:00 |
141125_Press release progress share buy back program Fagron - NL.pdf
|
Dutch | 157.2 KB | ||
| 2025-11-07 18:00 |
071125_Press release progress share buy back program Fagron - ENG.pdf
|
English | 156.1 KB | ||
| 2025-11-07 18:00 |
071125_Press release progress share buy back program Fagron - NL.pdf
|
Dutch | 157.8 KB | ||
| 2025-10-09 07:00 |
Fagron Q3 2025 press release.pdf
|
English | 281.1 KB | ||
| 2025-10-09 07:00 |
Fagron Q3 2025 press release NL.pdf
|
Dutch | 339.9 KB | ||
| 2025-10-06 07:00 |
Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acqui…
|
English | 590.7 KB | ||
| 2025-10-06 07:00 |
Fagron verkrijgt goedkeuring door de mededingingsautoriteit in Brazilië voor de…
|
Dutch | 488.0 KB | ||
| 2025-09-29 19:00 |
Press release increase share capital 29 September 2025.pdf
|
English | 148.8 KB | ||
| 2025-09-29 19:00 |
Persbericht verhoging kapitaal 29 september 2025.pdf
|
Dutch | 124.3 KB | ||
| 2025-09-25 07:00 |
Fagron announces the acquisition of UCP in North America and FDA inspection upd…
|
English | 166.2 KB | ||
| 2025-09-25 07:00 |
Fagron kondigt de overname van UCP in Noord-Amerika aan en een update over de F…
|
Dutch | 172.5 KB | ||
| 2025-07-31 08:22 |
Fagron delivers strong performance with 11% topline growth and 12% increase in …
|
English | 209.5 KB |
Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Fagron N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Fagron N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-23 | Pulido Andrew | Executive member | Sell | 85,000 | 1,803,351.50 EUR |
| 2025-05-22 | Pulido Andrew | Executive member | Buy | 85,000 | 1,617,550.00 EUR |
| 2025-05-02 | De Jong Cornelia Neeltje | Board | Sell | 12,689 | 263,834.55 EUR |
| 2025-04-30 | De Jong Cornelia Neeltje | Board | Sell | 229 | 4,660.15 EUR |
| 2025-04-29 | De Jong Cornelia Neeltje | Board | Sell | 10,000 | 201,500.00 EUR |
| 2025-03-28 | J. Verlinden | Other | Buy | 24,551 | 453,702.48 EUR |
| 2025-03-28 | J. Verlinden | Other | Sell | 17,930 | 344,047.56 EUR |
| 2025-03-27 | Padilla Rafael | Board | Buy | 78,469 | 1,450,107.12 EUR |
| 2025-03-27 | De Jong Cornelia Neeltje | Board | Buy | 45,418 | 839,324.64 EUR |
| 2025-02-21 | Bakker Vera | Executive member | Buy | 773 | 15,000.00 EUR |
Peer Companies
